Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.51 |
| ▸ | F2 | P00734 | 2/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.50 |
| ▸ | F10 | P00742 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21822512 | 0.92 | DRD4 (0.50) | DRD4F2ST14F10PRSS1 | |
| SCHEMBL28598763 | 0.90 | SLC6A5 (0.49) | DRD4F2ST14F10PRSS1 | |
| SCHEMBL21822299 | 0.88 | DRD4 (0.50) | DRD4F10SLC6A5TEAD1DRD2 | |
| SCHEMBL21822334 | 0.88 | DRD4 (0.49) | DRD4F2ST14F10PRSS1 | |
| SCHEMBL25015660 | 0.86 | DRD4 (0.48) | DRD4F2ST14F10PRSS1 | |
| SCHEMBL21822166 | 0.86 | CCR9 (0.48) | DRD4F10SLC6A5TEAD1DRD2 | |
| SCHEMBL25017270 | 0.85 | DRD4 (0.47) | DRD4F2F10PRSS1SLC6A5 | |
| SCHEMBL28588320 | 0.84 | SLC6A5 (0.48) | DRD4F2F10PRSS1SLC6A5 | |
| SCHEMBL21822510 | 0.82 | F10 (0.47) | DRD4F2F10PRSS1SLC6A5 | |
| SCHEMBL21822344 | 0.82 | ST14 (0.55) | DRD4F2ST14F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3860636-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | Disc Medicine, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072580-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. (US) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | DRD4 4826/4885F2 408/4885ST14 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.